Boston Scientific Launches Large-Scale Registry for New Drug-Eluting Stent System

Boston Scientific Corporation has begun enrolling patients in a significant registry to evaluate the efficacy and safety of its new Taxus Liberte paclitaxel-eluting stent system. The Taxus OLYMPIC registry will enroll more than 30,000 patients at over 600 centers across the United States, Europe, and other international locations. This ambitious study aims to collect real-world data on the stent's performance in treating patients with coronary artery disease. The registry is divided into five phases, corresponding to the commercial introduction of the Taxus Liberte system in different regions of the world.

Key Takeaways:

• The Taxus OLYMPIC registry will enroll more than 30,000 patients across over 600 centers worldwide.
• The registry is designed to collect real-world data on the efficacy and safety of the Taxus Liberte paclitaxel-eluting stent system in treating patients with coronary artery disease.
• The OLYMPIC registry will enroll patients in five phases, corresponding to the commercial introduction of the Taxus Liberte system in different regions of the world.
• The initial phase of the registry will enroll 500 patients.
• The registry demonstrates Boston Scientific's commitment to leadership and innovation in the field of drug-eluting stents.
• Physicians such as Waqar H. Ahmed, MD, MS, FACC, at King Fahed Armed Forces Hospital in Jeddah, Saudi Arabia, will participate in the registry.

Statistics:

• Over 30,000 patients will be enrolled in the Taxus OLYMPIC registry.
• The registry will be conducted at over 600 centers worldwide.
• The initial phase of the registry will enroll 500 patients.
• The OLYMPIC registry is designed to collect data on the Taxus Liberte stent system in 5 years.

Sources:

• "Boston Scientific Commences Enrollment in Patient Registry for Taxus Liberte Stent System" by Biotech Business Week, 2005, NewsRx.com.